According to Market Research Future (MRFR), the global hemoglobinopathies market is projected to rise significantly over the forecast period. The market held a valuation of USD 5.800 million in 2018 and is predicted to experience a CAGR of about 10.2% from 2019 to 2025 (forecast period). The report provides a comprehensive overview of the present scenario, the economic condition, and the COVID-19 analysis of the overall market.

Hemoglobinopathy is a group of blood disorders such as sickle cell disease, thalassemia, and many others. It is considered the most common genetic disorder in the world. Hemoglobinopathies have also become much more prevalent in central and northern Europe, like Germany, due to immigration.

Market Dynamics

The increased incidence of hemoglobin disorders such as sickle cell anemia, thalassemia, Hb C, and Hb E is expected to be a high-impact market factor. As per the WHO, hemoglobin disorders are prevalent in more than 60% of the 229 countries, with over 70% of births. As per the study published by the Centers for Disease Control and Prevention ( CDC) in 2015, the initial screening of newborns for the diagnosis of sickle cell disease (SCD) and other hemoglobin disorders such as alpha (α) and beta (β) thalassemia has also earned considerable attention in recent years due to changes in US demographics.

Unhygienic and inadequate healthcare services are some of the factors leading to a rise in the target population base in low-income regions such as South East Asia, the Mediterranean basin, and the African region that will drive demand growth over the forecast period.

Market Segmentation

The global market for hemoglobinopathies has been segmented based on type, treatment, and end-users.

By type, the global market for hemoglobinopathies has been segmented into thalassemia, sickle cell disease, and other Hb variants diseases. Thalassemia is further classified as alpha-thalassemia and beta-thalassemia. The sickle cell disease segment is projected to hold the largest market share of the hemoglobinopathies market. This is due to the existence of robust product pipelines such as Lent Globin and the rising prevalence of sickle cell disease.

Based on treatment, the global market for hemoglobinopathies has been classified into stem-cell transplantation, blood transfusions, analgesics, antibiotics, ACE inhibitors, and hydroxyurea. The blood transfusion segment holds the largest market share due to a high success rate and the increased acceptance of this treatment option.

By the end-user, the global market for hemoglobinopathies has been classified into hospitals and clinics, diagnostics laboratories, and others. 

Regional Analysis

Regionally, the global market for hemoglobinopathies has been segmented into four global regions, namely, the Americas, Europe, Asia Pacific, and the Middle East and Africa.

The Americas dominated the global market for hemoglobinopathies due to the increasing geriatric population in the world. As indicated by the American Society of Hematology, approximately 70,000 to 100,000 Americans have sickle cell disease, the most severe type of inherited blood disorder. As reported by the Centers for Disease Control and Prevention (CDC) in 2010, the US incidence rate for sickle cell trait (based on information provided by 13 states) was 73.1 cases per 1,000 black newborns, 2.2 cases per 1,000 Asian or Pacific Islander newborns, and 3.0 cases per 1,000 white newborns. The incidence rates for Hispanic ethnicity (within 13 states) is 6.9 cases per 1,000 Hispanic newborns. The rising participation of industry players also has a significant effect on the development of America's industry for hemoglobinopathies. For example, Sanofi launched the first approved treatment for acquired thrombotic thrombocytopenic purpura (aTTP) in Europe in 2018, bringing a new treatment option to patients who previously had none. In the USA, this treatment was approved by the FDA in February 2019. As per the Centers for Disease Control and Prevention (CDC), SCD affects nearly 100,000 Americans, with approximately one in 365 Black or African American births.

The Asia Pacific is expected to represent incredible market growth throughout the forecast period due to the increasing prevalence of hemoglobin disorders such as sickle cell anemia, thalassemia, Hb C, and Hb E.

The Middle East and Africa have had the least market share in global hemoglobinopathies market due to low economic growth, especially in the African region.

Key Players

Some of the key players identified by MRFR in the global market for hemoglobinopathies are Sanofi, Sangamo Therapeutics, Inc., Neusoft Medical Systems Co., Ltd, Bluebird Bio, Inc., Emmaus Life Sciences Inc., Prolong Pharmaceuticals, Global Blood Therapeutics, Celgene Corporation, Alnylam Pharmaceuticals, Gamida Cell, Acceleron Pharma, Mast Therapeutic, HemaQuest Pharmaceuticals, Invenux.